Kimball Electronics Inc. reported its second‑quarter 2026 results, posting net sales of $341.3 million—a 4.5% to 5% decline from the same period last year—while operating income rose to $10.8 million and adjusted operating income climbed to $15.3 million. Adjusted earnings per share were $0.28, slightly below the $0.29 reported a year earlier, and net income reached $3.6 million with adjusted net income of $6.9 million. The company’s gross margin improved to 8.2%, up 160 basis points from 6.6% a year ago, and its adjusted operating margin expanded to 4.5%, an 80‑basis‑point gain.
The decline in top line was driven primarily by a 5% drop in the Industrial vertical to $82.7 million and a 13% decline in the Automotive segment to $162.3 million. In contrast, the Medical vertical delivered double‑digit growth, expanding 15% year‑over‑year to $96.3 million, underscoring the company’s strategic shift toward higher‑margin medical contract manufacturing. The mix shift and the closure of the Tampa facility helped lift margins even as overall sales slipped.
Management highlighted that the company’s restructuring and cost‑control initiatives are paying off. CEO Richard Phillips noted that “sales in Q2 were in line with expectations, highlighted by another quarter of strong double‑digit year‑over‑year growth in the medical vertical, margins improved compared to the same period last year, and cash from operations was positive for the eighth consecutive quarter.” CFO Jana Croom added that favorable foreign‑exchange rates and the Tampa plant shutdown contributed to the margin improvement.
Kimball raised its fiscal‑2026 guidance, now projecting net sales of $1.40 billion to $1.46 billion and adjusted operating income of 4.2% to 4.5% of sales, up from the prior range of $1.35 billion to $1.45 billion and 4.0% to 4.25%. The upward revision reflects management’s confidence in continued demand in the medical vertical and the expansion of its higher‑margin contract manufacturing organization.
The results and guidance signal a company in transition: revenue is modestly down, but profitability is improving and the medical segment is a clear growth engine. The earnings beat on adjusted EPS—though slightly lower YoY—demonstrates effective cost discipline, while the revenue miss against consensus highlights the ongoing weakness in legacy industrial and automotive markets. The raised guidance indicates that executives expect the medical vertical to sustain its double‑digit growth and that the company’s restructuring will continue to deliver margin expansion. Overall, the earnings reinforce the narrative that Kimball is successfully pivoting toward a higher‑margin medical CMO model while managing legacy business headwinds.
The company’s strategic focus on medical contract manufacturing, coupled with the opening of a new Indianapolis facility and the rebranding to Kimball Solutions, positions it to capture a larger share of the long‑life‑cycle medical device market. The guidance increase and margin improvement suggest that the company’s restructuring efforts are yielding tangible results, providing a more favorable outlook for investors who prioritize sustainable profitability over short‑term revenue growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.